Ultimate Fighting Championship athletes will be the next group of players to participate in a multiphase clinical study on CBD’s effects on pain relief in their famously high impact sport. The league has announced that it is partnering with a Canadian cannabis company to examine the effects of non-psychoactive cannabinoids on its players’ health.
The study will be used to develop a line of hemp-derived topical treatments manufactured by Aurora Cannabis. Officials from the league say that care, recovery, injury, pain, and inflammation in the mixed martial artists will be gauged by the investigation.
Currently, 30 UFC athletes have signed up for the trial, which will be headed by a University of Alberta research scientist and Aurora’s VP of global research and medical affairs. They will receive support from a group of UFC Performance Institute sports performance researchers based in Las Vegas.
“Collaborating with Aurora is the best way to educate ourselves and our fighters about the impact of CBD on MMA athletes and our sport,” said Duncan French, UFC’s vice president of performance. “We want to apply science and see where it leads us. Ideally, these studies will give us the clarity we need to determine the effectiveness of